Elisabeth Åvall Lundqvist

Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial

Mansoor Raza Mirza, Elisabeth Åvall Lundqvist, Michael J. Birrer et al. · The Lancet Oncology · 2019 · 239 citations

Superiority Trial, Medicine, Gynecology +8

Pharmacogenetic Studies of Paclitaxel in the Treatment of Ovarian Cancer

Henrik Gréen, Peter Söderkvist, Per Rosenberg et al. · Basic & Clinical Pharmacology & Toxicology · 2008 · 119 citations · Full text

Serological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis

Ilvars Silins, Zhaohui Wang, Elisabeth Åvall Lundqvist et al. · Journal of General Virology · 1999 · 73 citations

EGFR protein overexpression and gene copy number increases in oral tongue squamous cell carcinoma

Michael Ryott, Darawalee Wangsa, Kerstin Heselmeyer‐Haddad et al. · European Journal of Cancer · 2009 · 72 citations · Full text

Tumor Biology, Egfr Protein Overexpression, Medicine +8

Protein markers of cancer-associated fibroblasts and tumor-initiating cells reveal subpopulations in freshly isolated ovarian cancer ascites

My Wintzell, Elisabet Hjerpe, Elisabeth Åvall Lundqvist et al. · BMC Cancer · 2012 · 66 citations · Full text